Search Results
Your search for 3 matches 15184 pages
Showing 4301 - 4350KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy for HER2-Positive Early Breast Cancer
In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease–free survival in the node-positive or intent-to-treat population of women with high-risk, HER2-positive early breast...
Pembrolizumab Shows Durable Antitumor Activity in Both Locally Advanced and Recurrent/Metastatic Squamous Cell Carcinomas
The results of the second interim analysis of the KEYNOTE-629 study of pembrolizumab in cutaneous squamous cell carcinoma confirmed durable antitumor activity in both the locally advanced and the recurrent/metastatic settings. Adverse events with pembrolizumab were generally consistent with its...
Cancer vs Non–Cancer-Related Deaths Among Older Patients Selected for Surgical Treatment
In a Canadian population-based cohort study reported in JAMA Surgery, Chesney et al found that the 5-year rate of cancer-related deaths exceeded that of non–cancer-related deaths among patients aged 70 or older undergoing surgery for cancer. Study Details The study used data from ICES (formerly...
Prostate Cancer Surgery Rates in Black vs White Men With Nonmetastatic Disease During the COVID-19 Pandemic
In a retrospective cohort study reported in JAMA Oncology, Bernstein et al found that prostatectomy rates during the initial wave of the COVID-19 pandemic were dramatically lower among Black men vs White men with previously untreated nonmetastatic prostate cancer. Study Details The study involved...
FDA Approves Pembrolizumab in Combination for High-Risk, Early-Stage Triple-Negative Breast Cancer
On July 26, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as a neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. The FDA also...
Benefits of Adjuvant Pembrolizumab in Melanoma Reinforced by EORTC 1325/KEYNOTE-054 Updates
Adjuvant anti–PD-1 antibody therapy is widely used for stage III melanoma, given the approvals of pembrolizumab and nivolumab. These approvals were based on significantly improved relapse-free survival in the CheckMate 238 trial of nivolumab compared with ipilimumab and the EORTC 1325/KEYNOTE-054...
Adjuvant Pembrolizumab Improves Distant Metastasis–Free Survival in Resected High-Risk Stage III Melanoma
As reported in The Lancet Oncology by Alexander M.M. Eggermont, MD, of Princess Máxima Center, Utrecht, the Netherlands, and colleagues, the pivotal phase III EORTC 1325/KEYNOTE-054 trial has shown significant improvement in the secondary endpoint of distant metastasis–free survival, as well as...
Lorlatinib for Metastatic ALK-Positive NSCLC
On March 3, 2021, lorlatinib was granted regular approval for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ALK-positive tumors as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA simultaneously approved the Ventana ALK (D5F3) CDx Assay ...
Pembrolizumab Combined With Chemotherapy for Advanced Esophageal or Gastroesophageal Junction Carcinoma
On March 22, 2021, pembrolizumab was approved for use in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (tumors with epicenter 1 to 5 cm above the gastroesophageal junction) carcinoma who...
Breast Cancer in 2030: Predictions From a Breast Cancer Luminary
According to George W. Sledge, Jr, MD, FASCO, Professor of Medicine in the Division of Oncology at Stanford University Medical Center, by the beginning of the next decade, clinicians will be aided by the use of artificial intelligence (AI) in many facets of care and by the approval of a wave of new ...
Expert Point of View: Fabrice André, MD, PhD
Fabrice André, MD, PhD, Director of Research and Professor of Medical Oncology at Institut Gustave Roussy, Villejuif, France, commented on the two studies that used the MammaPrint 70-gene signature to identify patients for de-escalation or escalation of endocrine therapy.1,2 The push to...
MINDACT Trial Shows ‘Excellent’ Outcomes in Ultra-Low–Risk Breast Cancer
Patients with ultra-low–risk breast cancer, as classified by the MammaPrint 70-gene assay, had “excellent” long-term outcomes regardless of clinical risk or receipt of adjuvant therapy, a new analysis of the MINDACT trial has shown.1 In a separate study, a retrospective analysis of the National...
Public Comment on National Coverage Analysis of Screening for Lung Cancer With Low-Dose Computed Tomography
The following letter is adapted from comments made to the Centers for Medicare and Medicaid Services (CMS) by the American College of Radiology, the GO2 Foundation for Lung Cancer, and the Society of Thoracic Surgeons. “The American College of Radiology, the GO2 Foundation for Lung Cancer, and the...
I’m Alive by Sheer Force of Will—and a Lot of Luck
From the moment I felt a searing pain go through my right breast, I had a premonition that something was very wrong. Although I couldn’t feel anything unusual when I did a breast self-exam, I made an appointment with my gynecologist for a more thorough clinical breast exam and a mammogram. Because...
The Compelling Story of Cystic Fibrosis and the Dawn of Precision Medicine
Woe to the child who tastes salty from a kiss on the brow” was a forbidding prophecy from Medieval Europe, presaging unknown disease. Today, we know that salty skin is a telltale sign of cystic fibrosis in children, a disease that eluded medical identification until 1938, when an American...
Bone-Protecting Agents Shown to Reduce Fracture Rate in Men With Metastatic Prostate Cancer
Prostate cancer experts have often stated it is important to add a bone-protecting agent for patients on treatment for metastatic castration-resistant prostate cancer. Recent evidence in support of this recommendation comes from a study presented during the 2021 ASCO Annual Meeting, confirming a...
Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
On March 10, 2021, the VEGF tyrosine kinase inhibitor tivozanib was approved for treatment of adults with relapsed or refractory advanced renal cell carcinoma following at least two prior systemic therapies.1,2 Supporting Efficacy Data Approval was based on findings in the open-label, phase III...
Dostarlimab-gxly for Mismatch Repair–Deficient Recurrent or Advanced Endometrial Cancer
On April 22, 2021, the PD-1 inhibitor dostarlimab-gxly was granted accelerated approval for treatment of adults with mismatch repair–deficient recurrent or advanced endometrial cancer, as determined by a U.S. Food and Drug Administration (FDA)-approved test, that has progressed on or following a...
American Ginseng
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Eugenie Spiguel, MSN, ANP-BC, and Jyothirmai Gubili, MS, focus on American...
Expert Point of View: Amit M. Oza, MD, MBBS
Invited discussant of the FORWARD II trial,1Amit M. Oza, MD, MBBS, concluded that bevacizumab and mirvetuximab soravtansine was a “very well tolerated and effective” combination with “encouraging activity,” even in patients previously treated with bevacizumab and weekly paclitaxel. Dr. Oza is Head ...
Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
On March 5, 2021, the CD19-directed genetically modified autologous T-cell immunotherapy axicabtagene ciloleucel was granted accelerated approval for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.1,2 Axicabtagene ciloleucel is...
B-Cell Acute Lymphoblastic Leukemia: Update on Clinical Trials
“Learning never exhausts the mind.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on treatments under study ...
Early-Phase Trial Finds Mirvetuximab Soravtansine Plus Bevacizumab Active in Recurrent Ovarian Cancer
In patients with recurrent ovarian cancer, the antibody-drug conjugate mirvetuximab soravtansine, given with bevacizumab, showed antitumor activity leading to durable responses in platinum-agnostic patients with strong expression of folate receptor alpha (FRα), researchers reported at the 2021 ASCO ...
Expert Point of View: Kostas Stamatopoulos, MD, PhD
In the phase III GLOW trial, the all-oral regimen of fixed-duration ibrutinib plus venetoclax as first-line treatment for older or unfit patients with chronic lymphocytic leukemia (CLL) showed superior efficacy compared with chlorambucil and obinutuzumab.1Kostas Stamatopoulos, MD, PhD, of the...
Sukhmani K. Padda, MD, to Direct Thoracic Medical Oncology at Cedars-Sinai Cancer Center
Thoracic medical oncologist Sukhmani K. Padda, MD, was recently selected to direct Thoracic Medical Oncology at Cedars-Sinai Cancer Center in Los Angeles. Dr. Padda’s appointment, following a national search, reflects her breadth of experience as a clinician and researcher in the field of thoracic...
Bringing Palliative Care to Native American Patients With Cancer
Native Americans are among the most underserved minority populations in the United States and are disproportionately affected by cancer. They have the lowest survival rates for nearly all types of cancer of any minority population and much higher rates of certain types of cancer, including lung,...
Phase III GLOW Trial: Improved Outcomes With First-Line Ibrutinib Plus Venetoclax in Elderly Patients With CLL
Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior outcomes compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL), based on the primary analysis of the phase III GLOW trial presented during the European Hematology...
Bridging the Gender Gap in Oncology
Women account for a growing proportion of the oncology workforce. Multiple studies, however, show that women oncologists are underrepresented in leadership positions, may have significantly lower salaries than men, and may be subjected to discriminatory practices stimulated by a medical culture...
Avapritinib for Advanced Systemic Mastocytosis
On June 16, 2021, avapritinib was approved for the treatment of adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.1,2 Avapritinib is not recommended...
Expert Point of View: Philip McCarthy, MD
Commenting on the updated results of the MAIA trial1 for The ASCO Post was Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York. Dr. McCarthy described how the...
Role of PI3K Inhibition in Indolent Lymphomas
As reported by Fowler et al in the Journal of Clinical Oncology1—and summarized in this issue of The ASCO Post—the international phase IIb UNITY-NHL trial of 208 patients with marginal zone lymphoma (MZL; n = 69), follicular lymphoma (FL; n = 117), and small lymphocytic lymphoma (SLL; n = 22)...
MAIA Update: Overall Survival Benefit Reported With Daratumumab Plus Lenalidomide in Myeloma
In an updated analysis of the phase III MAIA trial, the addition of the monoclonal antibody daratumumab to the immunomodulatory agent lenalidomide and the corticosteroid dexamethasone (D-Rd) significantly improved overall survival over lenalidomide/dexamethasone alone in patients newly diagnosed...
Dual PI3Kδ/CK1ε Inhibitor Umbralisib in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Nathan H. Fowler, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, a phase IIb trial (UNITY-NHL) has shown that the dual PI3Kδ/casein kinase (CK)1ε inhibitor umbralisib produced durable responses in patients with relapsed...
Factoring Fertility Preservation Into Breast Cancer Treatment
Breast cancer is the most commonly diagnosed cancer in women of reproductive age. Approximately 10% of breast cancers are diagnosed in this age group.1 Young age at diagnosis is an adverse prognostic factor, and most young women will be offered chemotherapy and/or endocrine therapy, both of which ...
Addition of Adavosertib to Gemcitabine Improves Outcomes in High-Grade Serous Ovarian Cancer
In a phase II trial reported in The Lancet, Stephanie Lheureux, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, found that the addition of the oral Wee1 inhibitor adavosertib to gemcitabine significantly improved progression-free and overall survival in...
Addition of Ipilimumab to Nivolumab in Previously Treated, Immunotherapy-Naive Patients With Stage IV Squamous NSCLC
As reported in JAMA Oncology by Scott N. Gettinger, MD, and colleagues, the phase III Lung Cancer Master Protocol S1400I trial showed no improvement in overall survival with the addition of ipilimumab to nivolumab in previously treated, immune checkpoint inhibitor–naive patients with stage IV...
Implementation of a Program Providing Free Cancer Screenings, Same-Day Results
Evidence shows that early detection and treatment of cancer can significantly improve health outcomes. However, women in Mississippi—particularly in underserved populations—experience high rates of late-stage cancer diagnoses. A report published by Michelle Williams, PhD, and colleagues in the...
Outcomes in Patients With HER2-Low–Positive Breast Cancer Participating in Neoadjuvant Clinical Trials
In a pooled analysis of individual patient data from breast cancer neoadjuvant clinical trials reported in The Lancet Oncology, Carsten Denkert, MD, and colleagues found that pathologic complete response and survival rates for patients with HER2-low–positive vs HER2-zero tumors differed according...
Expert Point of View: Carol Aghajanian, MD
“The phase III ENGOT/GCIG study1 proved to be negative, with no advantage seen with the extension of bevacizumab treatment,” said the abstract’s invited discussant, Carol Aghajanian, MD, Chief of the Medical Gynecologic Oncology Service at Memorial Sloan Kettering Cancer Center, New York. Dr....
Bevacizumab in Advanced Ovarian Cancer: Phase III Trial Finds More Is Not Better
In advanced ovarian cancer, the duration of maintenance bevacizumab should remain 15 months, according to the European multicenter phase III ENGOT/GCIG trial. These results were presented during the 2021 ASCO Annual Meeting by Jacobus Pfisterer, MD, PhD, of the AGO Study Group and Gynecologic...
Ruxolitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-vs-Host Disease After Allogeneic Stem Cell Transplantation
In the phase III REACH3 trial, reported in The New England Journal of Medicine, Robert Zeiser, MD, and colleagues found that ruxolitinib produced a significantly higher overall response rate vs investigator-selected control treatments in patients with glucocorticoid-refractory or -dependent chronic ...
Interleukin-2 Pathway Agonist Bempegaldesleukin Plus Nivolumab in the First-Line Treatment of Metastatic Melanoma
In the phase II cohort of a phase I/II trial (PIVOT-02) reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues found that the combination of the interleukin-2 pathway agonist bempegaldesleukin and nivolumab produced high response rates and extended progression-free survival in...
Pembrolizumab/Lenvatinib Granted Regular Approval for Advanced Endometrial Carcinoma
On July 21, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with lenvatinib (Lenvima) for patients with advanced endometrial carcinoma that is not microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR). These patients must have ...
Addition of AKT Inhibitor Ipatasertib to Abiraterone/Prednisolone in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss
In the phase III IPATential150 trial reported in The Lancet, Christopher Sweeney, MD, and colleagues found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in progression-free survival among patients with metastatic...
Addition of Prime-Boost Vaccination Regimen to Atezolizumab in Soft-Tissue Sarcomas Expressing NY-ESO-1
In a phase II trial reported in the Journal of Clinical Oncology, Sant P. Chawla, MD, and colleagues found that the addition of the heterologous prime-boost vaccination regimen CMB305 to atezolizumab did not improve survival outcomes in patients with soft-tissue sarcomas expressing the...
MRI-Targeted vs Standard Biopsy for Prostate Cancer Screening in Men With Elevated PSA Levels
In a Swedish population-based noninferiority trial (STHLM3-MRI) reported in The New England Journal of Medicine, Eklund et al found magnetic resonance imaging (MRI)-targeted biopsy was noninferior to standard biopsy in detecting clinically significant cancers in men with elevated prostate-specific...
Adding Perioperative Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA NSCLC
In a Swiss phase II trial (SAKK 16/14) reported in the Journal of Clinical Oncology, Rothschild et al found that the addition of perioperative durvalumab to neoadjuvant cisplatin/docetaxel resulted in a high major pathologic response rate and an event-free survival rate of 73% in patients with...
HER2-Specific CAR T-Cell Trial Addresses Pediatric Brain and Spinal Cord Tumors
Locoregional delivery of chimeric antigen receptor (CAR) T cells has resulted in objective responses in adults with glioblastoma, but the approach has not been evaluated in pediatric patients with brain and central nervous system tumors. The innovative, ongoing phase I BrainChild-01 trial is...
Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer
In a Canadian population-based retrospective cohort study reported in JAMA Oncology, Ethier et al identified real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine (T-DM1) for stage IV HER2-positive breast cancer, observing that outcomes appeared to be poorer than...
KIT Inhibitor Combination Shows Efficacy in Refractory GIST
In a phase Ib/IIa trial reported in JAMA Oncology, Wagner et al found that the combination of a type I KIT inhibitor, PLX9486, with the type II inhibitor sunitinib produced clinical benefit and improved progression-free survival rates in patients with refractory gastrointestinal stromal tumors...
